Interleukin-22 mitigates acute respiratory distress syndrome (ARDS).

ABSTRACT:

Background

The goal of this study was to determine if IL-22:Fc would Acute Respiratory Distress Syndrome (ARDS).

Summary background data

No therapies exist for ARDS and treatment is purely supportive. Interleukin-22 (IL-22) plays an integral component in recovery of the lung from infection. IL-22:Fc is a recombinant protein with a human FC immunoglobulin that increases the half-life of IL-22.

Study design

ARDS was induced in C57BL/6 mice with intra-tracheal lipopolysaccharide (LPS) at a dose of 33.3 or 100 ug. In the low-dose LPS group (LDG), IL-22:FC was administered via tail vein injection at 30 minutes (n = 9) and compared to sham (n = 9). In the high-dose LPS group (HDG), IL-22:FC was administered (n = 11) then compared to sham (n = 8). Euthanasia occurred after b

SUBMITTER: Taghavi S 

PROVIDER: S-EPMC8486146 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature